Company / Depreciation & Amortization
Travere Therapeutics, Inc. Depreciation & Amortization History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Depreciation & Amortization
$60.7M
FY2025
5-year range
$20.4M / $60.7M
FY2021-FY2025
Trend
+39.5%
vs FY2024
Sector context
#28 of 168
Health Care
What the data says
Travere Therapeutics, Inc.'s depreciation & amortization of $61M is higher than 83% of companies in the Health Care sector (FY2025). Depreciation & Amortization has increased for 9 consecutive years, from $5M in FY2016 to $61M in FY2025.
Based on SEC 10-K filings.
$61M in FY2025 with a 5-year CAGR of +26.6%. Top quartile in the Health Care sector.
Increased from $39M to $61M over the past 2 years.
Health Care sector context is included.
Depreciation & Amortization over time
Growth rates
- 3-Year CAGR
- +43.1%
- 5-Year CAGR
- +26.6%
- 10-Year CAGR
- -
Sector benchmark
-71.5% below sector average
Key checks
Key Insights
- Travere Therapeutics, Inc.'s depreciation & amortization has grown for 9 consecutive years.
- 5-year CAGR of +26.6%, indicating consistent growth.
- In FY2025, depreciation & amortization increased 39.5% year-over-year.
- Ranks #28 out of 168 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -1.15 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Depreciation & AmortizationValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $60.7M | +39.5% |
| FY2024 | $43.6M | +13.0% |
| FY2023 | $38.5M | +86.0% |
| FY2022 | $20.7M | +1.5% |
| FY2021 | $20.4M | +9.3% |
| FY2020 | $18.7M | +4.9% |
| FY2019 | $17.8M | +10.3% |
| FY2018 | $16.1M | +20.5% |
| FY2017 | $13.4M | +148.0% |
| FY2016 | $5.4M | -59.7% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026